Company Description
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.
It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases.
Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan.
Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
| Country | Japan |
| Founded | 1925 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 7,604 |
| CEO | Dr. Osamu Okuda |
Contact Details
Address: 120 Broadway, 32nd Floor New York, New York 10271 United States | |
| Phone | 212-238-3010 |
| Website | chugai-pharm.co.jp |
Stock Details
| Ticker Symbol | CHGCY |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001453934 |
| CUSIP Number | 171269103 |
| ISIN Number | US1712691039 |
Key Executives
| Name | Position |
|---|---|
| Dr. Osamu Okuda | President, Chief Executive Officer and Representative Director |
| Toshiaki Itagaki | Head of Finance Supervisory Division, Chief Financial Officer and Executive Vice President |
| Toshiya Sasai | Executive of Investor Relations Group and Corporate Communications Department |
| Shinji Hidaka | Executive Vice President and Head of Marketing and Sales Division |
| Junichi Ebihara | Executive Vice President |
| Dr. Yoshiaki Ohashi | SVice President and Full-time Audit Supervisory Board Member |
| Tetsuya Yamaguchi | Executive Vice President and Head of Project, Lifecycle Management and Foundation Medicine Unit |
| Yoshiyuki Yano | Executive Vice President |
| Satoko Shisai | Executive Vice President and Head of Digital Transformation Unit |
| Dr. Shigehiro Yamada Ph.D. | Head of Sustainability Department and Full-Time Audit and Supervisory Board Member |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 2, 2020 | F-6 POS | Post-effective amendments for immediately effective filing |
| Nov 22, 2019 | F-6EF | Registration of American Depository Receipt shares, immediately effective |
| Sep 27, 2017 | F-6EF | Registration of American Depository Receipt shares, immediately effective |
| Jan 14, 2009 | F-6EF | Registration of American Depository Receipt shares, immediately effective |